Bristol-Myers Squibb expands R&D presence in hubs of world-class science and innovation
BMS scientists will focus on the company's ongoing discovery efforts in genetically defined diseases, molecular discovery technologies and discovery platform chemistry in state-of-the-art lab space
Bristol-Myers Squibb has announced important next steps in the evolution of the company's R&D organisation, including plans to expand its presence in hubs of scientific excellence and innovation with the opening of a new state-of-the-art research site in Cambridge (Massachusetts, US) in addition to the ongoing expansion of the company's R&D site in the San Francisco Bay area.
The new facility in Cambridge is expected to open in 2018. The ongoing site expansion in San Francisco adds 61,000ft2 of laboratory and office space at the Woodside Technology Park life science campus and is expected to be completed in 2016.
Consistent with evolution of the R&D organisation's strategic focus, the company also announced plans to discontinue discovery research efforts in virology. This decision does not affect the company's promising ongoing clinical development programme in virology, nor does it have an impact on the company's marketed products in virology.
‘In addition to investments in central New Jersey, our new location in Cambridge and our expanding presence in San Francisco positions the company and our scientists in the heart of vibrant ecosystems of world-class science, innovation and business opportunities, which offer ideal environments for fostering external collaboration,’ said Francis Cuss, Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb.
‘Ultimately, our goal is to continue to accelerate the translation of scientific knowledge and insights into the next wave of potentially transformational medicines for patients with serious diseases,’ he added.